|
|
Post by prcgorman2 on Jan 13, 2023 10:35:52 GMT -5
Fair to say an alternate view of reality. Can't actually be anything else. None of can know exactly how another person really thinks or feels. But, we can outline the arguments for what we claim we believe. I try to do that. It's more work than name calling or inferring someone is out-of-touch with reality, but also more respectable. I'll keep it simple. I can and do defend Mike's overall performance. I also want more. I can and will defend some things Mike has done but he was hired to sell afrezza. How have afrezza sales increased since Mike joined in 2016? How has he positioned it to capture both the T1 and T2s market? How long did it take to put the kids study together for the T1 market when we knew Al made the pump market by going after the kids? Mango said "Blaming Mike is disingenuous" when it comes to Mike not making more progress with the SoC. What I heard yesterday was afrezza in now for the T1 market and V-Go is for the T2 market. Not only has Mike not done the proper spade work for SoC changes but now he has thrown the towel in on the $40B T2 market for afrezza. If you can defend Mike with regard to afrezza, please do. I would love to get your perspective. At this point I would be happy with just 10% of the T2 market. BTW - Mike is getting paid a lot of money and has acquired a lot of stock. What was the pps when Mike joined in 2016 and what growth have we seen??? If we use pps to measure overall performance as our metric, please defend his performance. Sayhey, I'm a fan. I completely agree with you that more should be done to market Afrezza. I think it is too severe to assume Mike "has thrown in the towel". The SP of 2016 was headed into the toilet because of everything that happened before Mike got here, especially "toxic" debt and the 1:5 reverse split. Mike was handed a feces sandwich. Current fundamentals outlook is very promising. That's good work in 5 or 6 years. But no resting on laurels. More is needed. Another successful molecule and/or another partner. Meaningful improvement in Afrezza sales from a successful pediatric trial. Meaningful improvement in insurance coverage. (It's 2023, is there a useful improvement in Medicare coverage of inhaled insulin, or not?) I'm serious about these things. Just because I'm a fan of Mike's doesn't mean I'll stay that way. I 1000% agree with you that the potential of 10% of T2 sales should absolutely be exploited. I think your passion is excellent and your suggestions to work on accomplishing that incursion to the T2 market are innovative if not ingenious and I genuinely wish you had effective influence in Mannkind, if not the board (of directors). So just like I like and will defend our CEO, you will have a tough time picking a fight with this fan of your contributions to this board. |
|
|
|
Post by sayhey24 on Jan 13, 2023 11:34:04 GMT -5
Peppy - I think we are all in violent agreement that Martine throwing MNKD the life line was a great day for MNKD. As Mike said yesterday now they can pay the bills. However, it has nothing to do with the SoC and the failure to do the proper work to justify changes. Its been 7 years.
When Mike got hired we had a sales force. Maybe he was a sales force of one but how many guys do you need to go through a preliminary discover process to figure out why the Endos where not prescribing back in 2016? Afrezza was on the market an entire year. I would think some of the feedback would have been for T2s is not part of the Standard of Care and for T1s it did not show any benefits in the Affinty 1 trial.
Back in 2016 I think they still had some money. Did Mike come back to Pfieffer and tell him this SoC is a big deal to sell afrezza? Did he say we need to get the trials going which Sanofi never did? Did it really need to take 7 years to figure out afrezza was being underdosed? It sure sounded that way from what Mike said yesterday. I think Sports said this years ago. I think my tag line was when dosing 'go big". We knew on this board the label was wrong with dosing. We also knew calling the cartridges "units" was casing all kinds of grief with T1s trying to calculate based on past RAA experience.
Before Martine things were looking pretty bad. Now we can pay the bills and take a breath but what do we do? We thrown in the towel on afrezza with the T2s and say that market is for V-Go. What step is V-Go in the SoC? Yep, the very last. At least now Mike doesn't need to try and move the ADA in making changes to the SoC. We are targeting a tiny market and the very last step.
|
|
|
|
Post by sayhey24 on Jan 13, 2023 11:47:59 GMT -5
I can and will defend some things Mike has done but he was hired to sell afrezza. How have afrezza sales increased since Mike joined in 2016? How has he positioned it to capture both the T1 and T2s market? How long did it take to put the kids study together for the T1 market when we knew Al made the pump market by going after the kids? Mango said "Blaming Mike is disingenuous" when it comes to Mike not making more progress with the SoC. What I heard yesterday was afrezza in now for the T1 market and V-Go is for the T2 market. Not only has Mike not done the proper spade work for SoC changes but now he has thrown the towel in on the $40B T2 market for afrezza. If you can defend Mike with regard to afrezza, please do. I would love to get your perspective. At this point I would be happy with just 10% of the T2 market. BTW - Mike is getting paid a lot of money and has acquired a lot of stock. What was the pps when Mike joined in 2016 and what growth have we seen??? If we use pps to measure overall performance as our metric, please defend his performance. Sayhey, I'm a fan. I completely agree with you that more should be done to market Afrezza. I think it is too severe to assume Mike "has thrown in the towel". The SP of 2016 was headed into the toilet because of everything that happened before Mike got here, especially "toxic" debt and the 1:5 reverse split. Mike was handed a feces sandwich. Current fundamentals outlook is very promising. That's good work in 5 or 6 years. But no resting on laurels. More is needed. Another successful molecule and/or another partner. Meaningful improvement in Afrezza sales from a successful pediatric trial. Meaningful improvement in insurance coverage. (It's 2023, is there a useful improvement in Medicare coverage of inhaled insulin, or not?) I'm serious about these things. Just because I'm a fan of Mike's doesn't mean I'll stay that way. I 1000% agree with you that the potential of 10% of T2 sales should absolutely be exploited. I think your passion is excellent and your suggestions to work on accomplishing that incursion to the T2 market are innovative if not ingenious and I genuinely wish you had effective influence in Mannkind, if not the board (of directors). So just like I like and will defend our CEO, you will have a tough time picking a fight with this fan of your contributions to this board. Wait a minute. For some reason I thought Sanofi gave us a lot of money going into 2016 when Mike showed up. If I remember correctly, Mike asked for the CEO job when Dwayne was a no show for the job. Mike during 2016 was the CEO in waiting and the pps was higher than it is today. Mike helped create this mess. He was not just handed it after the fact. Everyone wants to give Mike credit for saving MNKD. Lets not forget he helped create the mess. 2016 was not a good year for MNKD and then things got worse and worse until Martine. Now we have MNKD 3.0 for 2023. We were told yesterday afrezza is for the T1 market and V-Go is for the T2 market. Thats where we are. No mention of the TS GLP1 patent. No T2 afrezza trials with GLP1s. It is what it is. We are putting V-Go in the reps "bags" and thats the T2 strategy. I hope he rethinks his strategy but I am 100% confident that going after the T2 market with afrezza scares Mike. |
|
|
|
Post by Thundersnow on Jan 13, 2023 19:46:18 GMT -5
Sayhey, I'm a fan. I completely agree with you that more should be done to market Afrezza. I think it is too severe to assume Mike "has thrown in the towel". The SP of 2016 was headed into the toilet because of everything that happened before Mike got here, especially "toxic" debt and the 1:5 reverse split. Mike was handed a feces sandwich. Current fundamentals outlook is very promising. That's good work in 5 or 6 years. But no resting on laurels. More is needed. Another successful molecule and/or another partner. Meaningful improvement in Afrezza sales from a successful pediatric trial. Meaningful improvement in insurance coverage. (It's 2023, is there a useful improvement in Medicare coverage of inhaled insulin, or not?) I'm serious about these things. Just because I'm a fan of Mike's doesn't mean I'll stay that way. I 1000% agree with you that the potential of 10% of T2 sales should absolutely be exploited. I think your passion is excellent and your suggestions to work on accomplishing that incursion to the T2 market are innovative if not ingenious and I genuinely wish you had effective influence in Mannkind, if not the board (of directors). So just like I like and will defend our CEO, you will have a tough time picking a fight with this fan of your contributions to this board. Wait a minute. For some reason I thought Sanofi gave us a lot of money going into 2016 when Mike showed up. If I remember correctly, Mike asked for the CEO job when Dwayne was a no show for the job. Mike during 2016 was the CEO in waiting and the pps was higher than it is today. Mike helped create this mess. He was not just handed it after the fact. Everyone wants to give Mike credit for saving MNKD. Lets not forget he helped create the mess. 2016 was not a good year for MNKD and then things got worse and worse until Martine. Now we have MNKD 3.0 for 2023. We were told yesterday afrezza is for the T1 market and V-Go is for the T2 market. Thats where we are. No mention of the TS GLP1 patent. No T2 afrezza trials with GLP1s. It is what it is. We are putting V-Go in the reps "bags" and thats the T2 strategy. I hope he rethinks his strategy but I am 100% confident that going after the T2 market with afrezza scares Mike. Sayhey....You love to hammer Mike but you are forgetting an important factor. MNKD was a mess LITERALLY. The company was in SHAMBLES. As Mike said they were down to 1 month of OP CASH. Mike inherited a horrible company. I love Al Mann just as much as you but his decision to hire Hakan (God rest his soul) was not smart. Yes he was there for 10 years and was a good friend of Al's but clearly it was a very bad mistake. Yes they got a ton of money from Sanofi with the termination fee (~$150M) but that was used to CLEAN UP the mess and create a sales organization. There is nothing I am writing that is new to you. Mike has turned this company around which you can see with the stock price. A low of $.87 to >$5.00 is what I would call a turnaround. I give Martine limited credit in helping MNKD. Martine saw a great technology and licensed it. It's an equal partnership. I don't think Martine picked MNKD/Al Mann out of the goodness of her heart. She doesn't operate that way. Everything is business with her and she made the right business decision. MNKD is entering a new phase and the next 5 years will bring tremendous growth. MNKD is hitting their stride and now they have to execute. Mike has developed a strong strategic plan and has to implement. Regarding T1 v T2....Mike understands the challenges with the Type 2 market. He knows the only way to convert them is to get the Type 1's onboard and hopefully it will trickle over to the Type 2 market. As I've said many times T2's want to take a pill and now SGLT2 shot before they take insulin. The stigma around insulin is too strong. That's why if they show KIDS taking Afrezza they will switch but that's 4-5 years from now. |
|
|
|
Post by mytakeonit on Jan 13, 2023 20:37:42 GMT -5
I remember buying shares of MNKD between $.80 to $.88 ... one of my accounts still has 8k shares at $.82 purchased on 05/02/17.
But, that's mytakeonit
BTW, V-Go was purchased primarily to gain a huge sales force with established clientele.
Date Open High Low Close* Adj Close** Volume
May 09, 2017 1.0500 1.2000 1.0300 1.1200 1.1200 9,231,500
May 08, 2017 0.8300 1.1800 0.8000 1.0100 1.0100 11,391,900
May 05, 2017 0.7200 0.8200 0.6900 0.8000 0.8000 2,932,600
May 04, 2017 0.7700 0.7800 0.6900 0.7200 0.7200 2,051,600
May 03, 2017 0.8000 0.8200 0.6700 0.7100 0.7100 2,349,900
May 02, 2017 0.8300 0.8400 0.7800 0.8000 0.8000 1,455,500
|
|
|
|
Post by phdedieu12 on Jan 15, 2023 12:47:24 GMT -5
Sayhey, I'm a fan. I completely agree with you that more should be done to market Afrezza. I think it is too severe to assume Mike "has thrown in the towel". The SP of 2016 was headed into the toilet because of everything that happened before Mike got here, especially "toxic" debt and the 1:5 reverse split. Mike was handed a feces sandwich. Current fundamentals outlook is very promising. That's good work in 5 or 6 years. But no resting on laurels. More is needed. Another successful molecule and/or another partner. Meaningful improvement in Afrezza sales from a successful pediatric trial. Meaningful improvement in insurance coverage. (It's 2023, is there a useful improvement in Medicare coverage of inhaled insulin, or not?) I'm serious about these things. Just because I'm a fan of Mike's doesn't mean I'll stay that way. I 1000% agree with you that the potential of 10% of T2 sales should absolutely be exploited. I think your passion is excellent and your suggestions to work on accomplishing that incursion to the T2 market are innovative if not ingenious and I genuinely wish you had effective influence in Mannkind, if not the board (of directors). So just like I like and will defend our CEO, you will have a tough time picking a fight with this fan of your contributions to this board. Everyone wants to give Mike credit for saving MNKD. Lets not forget he helped create the mess. 2016 was not a good year for MNKD and then things got worse and worse until Martine. No MC, no Mannkind, there I fixed it for you! If it were any other human being at the helm you wouldn't have this board to discuss him or the company |
|
|
|
Post by sayhey24 on Jan 15, 2023 19:29:36 GMT -5
Everyone wants to give Mike credit for saving MNKD. Lets not forget he helped create the mess. 2016 was not a good year for MNKD and then things got worse and worse until Martine. No MC, no Mannkind, there I fixed it for you! If it were any other human being at the helm you wouldn't have this board to discuss him or the company I have no idea what you are talking about. God rest his soul but if Al had not gotten sick I would be shocked if MNKD and afrezza were not in a much different place right now. If Duane DeSisto had showed up who knows but Duane knew the industry. I had always held out hope Chris Viehbacher might have stepped in at some point after 2016. I think Chris would have gotten us to a better place. He sure seems to be doing well at Biogen. The reality is Mike is a great guy who has never run a company before and knew nothing about the diabetes industry and still seems to be an outsider. Aside from hiring Dave Kendall who does know the industry Mike has been learning by trial and error and error. Why he could not keep Dave around is still a mystery. The last trial by error being the $6M "Seeing is Believing" 3 month failure but maybe its really the V-Go purchase but time will tell on that one. tarheel told me V-Go is going to be one of our 4 revenue streams so how could I not be excited about V-Go. BTW - don't ask me to name all 4 revenue streams in 2023. For 2023 we will take things easy waiting on the kids submission in 2024. With the 2023 plan he laid out we don't have to worry about things like disrupting the T2 market with afrezza. Lets just play things safe. We now have V-Go as the go to for the $40B T2 market and its going into the sales reps "bags" this week. PHD - V-Go should capture how much of that $40B market - .025%? All is good. No worries about shelfing afrezza for the T2 $40B market nor keeping TS GLP1 in the freezer. We have a plan and it is what it is and I can still post on this board thanks to MC. Of course my pps is not $50 like it use to be nor $100 like it should be and won't be any time soon with our 2023 plan. |
|
|
|
Post by sayhey24 on Jan 15, 2023 19:45:00 GMT -5
Wait a minute. For some reason I thought Sanofi gave us a lot of money going into 2016 when Mike showed up. If I remember correctly, Mike asked for the CEO job when Dwayne was a no show for the job. Mike during 2016 was the CEO in waiting and the pps was higher than it is today. Mike helped create this mess. He was not just handed it after the fact. Everyone wants to give Mike credit for saving MNKD. Lets not forget he helped create the mess. 2016 was not a good year for MNKD and then things got worse and worse until Martine. Now we have MNKD 3.0 for 2023. We were told yesterday afrezza is for the T1 market and V-Go is for the T2 market. Thats where we are. No mention of the TS GLP1 patent. No T2 afrezza trials with GLP1s. It is what it is. We are putting V-Go in the reps "bags" and thats the T2 strategy. I hope he rethinks his strategy but I am 100% confident that going after the T2 market with afrezza scares Mike. Sayhey....You love to hammer Mike but you are forgetting an important factor. MNKD was a mess LITERALLY. The company was in SHAMBLES. As Mike said they were down to 1 month of OP CASH. Mike inherited a horrible company. I love Al Mann just as much as you but his decision to hire Hakan (God rest his soul) was not smart. Yes he was there for 10 years and was a good friend of Al's but clearly it was a very bad mistake. Yes they got a ton of money from Sanofi with the termination fee (~$150M) but that was used to CLEAN UP the mess and create a sales organization. There is nothing I am writing that is new to you. Mike has turned this company around which you can see with the stock price. A low of $.87 to >$5.00 is what I would call a turnaround. I give Martine limited credit in helping MNKD. Martine saw a great technology and licensed it. It's an equal partnership. I don't think Martine picked MNKD/Al Mann out of the goodness of her heart. She doesn't operate that way. Everything is business with her and she made the right business decision. MNKD is entering a new phase and the next 5 years will bring tremendous growth. MNKD is hitting their stride and now they have to execute. Mike has developed a strong strategic plan and has to implement. Regarding T1 v T2....Mike understands the challenges with the Type 2 market. He knows the only way to convert them is to get the Type 1's onboard and hopefully it will trickle over to the Type 2 market. As I've said many times T2's want to take a pill and now SGLT2 shot before they take insulin. The stigma around insulin is too strong. That's why if they show KIDS taking Afrezza they will switch but that's 4-5 years from now. How much money did MNKD have when Mike was hired? BTW - The T1 and T2 market are completely different. From day one Mike never developed a T2 plan. His plan has always been to sell to the endos. How many T2s go to endo's when they are first diagnosed? Mike told us last week our T2 plan is to sell V-Go. I have no idea who prescribes V-Go. At this point of care the T2 is in such bad shape they not only need the basal but they also need the meal time. This is step 5 in the SoC. Thats 4 shots a day for the T2 who use to take the 1 pill metformin. When afrezza was costing the Medicare patient $1500 a month no one was going to buy it. Now its $35. Tell me what my sales pitch is for the MNKD sales rep who has both V-Go and afrezza in their "bag". Mike said V-Go is for the T2s - OK. What would I say as a rep trying to sell V-Go? How about - "Look I know I rep both afrezza and V-Go and I know if you prescribe afrezza it will be 1. cheaper 2. provide better control and 3. be a lot easy and less work for the PWD but listen I got this V-Go in my bag and I really need to get rid of it??? Come on - what is my sales pitch??? Then Mike told us during the 3Q2022 call we would be hearing more about other uses for V-Go in January. I am waiting. Last week he again mentioned potential other uses. I am waiting. This is a spring controlled contraption. You can't regulated it. If you need a different insulin dose you have to get a different model V-Go. I sure hope Mike has another use for it but I will be surprised. |
|
|
|
Post by longliner on Jan 15, 2023 20:04:00 GMT -5
I believe the "rescue inhaler" will become a standard of care, as CGM's become the standard of care. Seeing is believing.
|
|
|
|
Post by phdedieu12 on Jan 16, 2023 21:40:51 GMT -5
No MC, no Mannkind, there I fixed it for you! If it were any other human being at the helm you wouldn't have this board to discuss him or the company I have no idea what you are talking about. God rest his soul but if Al had not gotten sick I would be shocked if MNKD and afrezza were not in a much different place right now. If Duane DeSisto had showed up who knows but Duane knew the industry. I had always held out hope Chris Viehbacher might have stepped in at some point after 2016. I think Chris would have gotten us to a better place. He sure seems to be doing well at Biogen. The reality is Mike is a great guy who has never run a company before and knew nothing about the diabetes industry and still seems to be an outsider. Aside from hiring Dave Kendall who does know the industry Mike has been learning by trial and error and error. Why he could not keep Dave around is still a mystery. The last trial by error being the $6M "Seeing is Believing" 3 month failure but maybe its really the V-Go purchase but time will tell on that one. tarheel told me V-Go is going to be one of our 4 revenue streams so how could I not be excited about V-Go. BTW - don't ask me to name all 4 revenue streams in 2023. For 2023 we will take things easy waiting on the kids submission in 2024. With the 2023 plan he laid out we don't have to worry about things like disrupting the T2 market with afrezza. Lets just play things safe. We now have V-Go as the go to for the $40B T2 market and its going into the sales reps "bags" this week. PHD - V-Go should capture how much of that $40B market - .025%? All is good. No worries about shelfing afrezza for the T2 $40B market nor keeping TS GLP1 in the freezer. We have a plan and it is what it is and I can still post on this board thanks to MC. Of course my pps is not $50 like it use to be nor $100 like it should be and won't be any time soon with our 2023 plan. It wasn't confusing, one sentence... If Al, If Duane, hoped, shoulda, coulda, no plan, blah blah blah, Mike doesn't know how to run a company, knows nothing about diabetes, blah blah, no plans, I get it!!!! Brilliant!!! |
|
|
|
Post by sayhey24 on Jan 17, 2023 9:48:28 GMT -5
I believe the "rescue inhaler" will become a standard of care, as CGM's become the standard of care. Seeing is believing. IMO this is a brilliant thought and something which could be achieved in 2023. Is MNKD working on doing this? MNKD should have more than enough data to be able to put a paper together for ADA 2023. The deadline is 3/31 for late submission. In the past we have talked about a "new" product which could be introduced "Afrezza Rescue" or "afrezza-R" which would be prescribed as a "rescue tool". There are a ton of T1s now using afrezza as an addition to their RAA for when they get the stubborn highs. Having afrezza included in the SoC specific for dealing with this condition would seem to be a unique use for afrezza other insulins can't provide. At the same time afrezza is not disrupting the current RAA treatment but is rather an add on. If in the SoC it would seem like an easy sell for the reps and insurance companies should cover. I was looking for Matt Bendall's coke challenge but I don't think its available anymore. Here is something Eric Fenar put together www.youtube.com/watch?v=xkOVPAikJm0 |
|
|
|
Post by akemp3000 on Jan 17, 2023 11:10:27 GMT -5
Just saw the article that came out a few hours ago titled, "Investors Will Be Pleased with Their Impressive 183% Return Over the Past Three Years". Granted the years prior sucked but this company is finally on a very good roll and looking to get better. GLTA
|
|
|
|
Post by phdedieu12 on Jan 17, 2023 11:28:04 GMT -5
Just saw the article that came out a few hours ago titled, "Investors Will Be Pleased with Their Impressive 183% Return Over the Past Three Years". Granted the years prior sucked but this company is finally on a very good roll and looking to get better. GLTA I second that sentiment. It certainly looks like we've turned the corner with a lot of upside |
|
|
|
Post by cretin11 on Jan 17, 2023 11:53:24 GMT -5
I have no idea what you are talking about. God rest his soul but if Al had not gotten sick I would be shocked if MNKD and afrezza were not in a much different place right now. If Duane DeSisto had showed up who knows but Duane knew the industry. I had always held out hope Chris Viehbacher might have stepped in at some point after 2016. I think Chris would have gotten us to a better place. He sure seems to be doing well at Biogen. The reality is Mike is a great guy who has never run a company before and knew nothing about the diabetes industry and still seems to be an outsider. Aside from hiring Dave Kendall who does know the industry Mike has been learning by trial and error and error. Why he could not keep Dave around is still a mystery. The last trial by error being the $6M "Seeing is Believing" 3 month failure but maybe its really the V-Go purchase but time will tell on that one. tarheel told me V-Go is going to be one of our 4 revenue streams so how could I not be excited about V-Go. BTW - don't ask me to name all 4 revenue streams in 2023. For 2023 we will take things easy waiting on the kids submission in 2024. With the 2023 plan he laid out we don't have to worry about things like disrupting the T2 market with afrezza. Lets just play things safe. We now have V-Go as the go to for the $40B T2 market and its going into the sales reps "bags" this week. PHD - V-Go should capture how much of that $40B market - .025%? All is good. No worries about shelfing afrezza for the T2 $40B market nor keeping TS GLP1 in the freezer. We have a plan and it is what it is and I can still post on this board thanks to MC. Of course my pps is not $50 like it use to be nor $100 like it should be and won't be any time soon with our 2023 plan. It wasn't confusing, one sentence... If Al, If Duane, hoped, shoulda, coulda, no plan, blah blah blah, Mike doesn't know how to run a company, knows nothing about diabetes, blah blah, no plans, I get it!!!! Brilliant!!! You seem to be mocking sayhey, but you were the one who said “ No MC, no Mannkind! If it were any other human being at the helm you wouldn't have this board to discuss him or the company” which is more far fetched than anything sayhey has ever posted. |
|
|
|
Post by phdedieu12 on Jan 17, 2023 12:03:39 GMT -5
It wasn't confusing, one sentence... If Al, If Duane, hoped, shoulda, coulda, no plan, blah blah blah, Mike doesn't know how to run a company, knows nothing about diabetes, blah blah, no plans, I get it!!!! Brilliant!!! You seem to be mocking sayhey, but you were the one who said “ No MC, no Mannkind! If it were any other human being at the helm you wouldn't have this board to discuss him or the company” which is more far fetched than anything sayhey has ever posted. Simply stated a fact, Mannkind is still in business because of MC, that's it. Nothing far fetched about that. I don't understand how anyone would question that, maybe except sayhey since he questions everything by his own admission, so no surprise there |
|
